The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras.
Open accessAbstract
Two dominant inhibitory Ras mutant proteins were analyzed by microinjection. One, [Asn-17]Ras, had a substitution in the putative Mg(2+)-binding site of Ha-Ras. The other, RAST, had a mutation in a yeast RAS protein that impaired its GTPase activity and increased its affinity for GAP. RAST also had a mutation that blocked its localization to the plasma membrane. In NIH 3T3 cells [Asn-17]Ras inhibited the function of normal Ras much more efficiently than that of oncogenic Ras. In contrast, RAST interfered with the transforming activity of oncogenic Ras more efficiently than that of normal Ras. These conclusions were based on two separate types of analysis. The inhibitory Ras mutant proteins were first microinjected into cells stably transformed either by oncogenic Ras or by high levels of expression of cellular Ras. Results obtained in stably transformed cells were then verified by coinjection of the inhibitory Ras mutant proteins together with transforming concentrations of either oncogenic or normal Ras protein. Whereas RAST was active in soluble form. [Asn-17]Ras required membrane localization for activity. Furthermore, mutations in the GAP/effector-binding domain reduced or eliminated the inhibitory activity of RAST but had no detectable effect on [Asn-17]Ras. These results are consistent with the possibility that [Asn-17]Ras functions by blocking the activation of endogenous Ras proteins, while RAST functions by blocking the ability of activated Ras to stimulate a downstream target within the cells. The properties of RAST suggest that interference with the GAP/effector-binding function of RAS represents a strategy for the preferential inactivation of oncogenic Ras in cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Cited by
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling
Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90164-8 · Cited by 3,652
cAMP Activates MAP Kinase and Elk-1 through a B-Raf- and Rap1-Dependent Pathway
Vossler, M. R., Yao, H., York, R. D., Pan, M.-G., Rim, C. S., & Stork, P. J. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80184-1 · Cited by 1,046
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
Mazure, N. M., Chen, E. Y., Laderoute, K. R., & Giaccia, A. J. (1997) · Blood · doi:10.1182/blood.v90.9.3322 · Cited by 503
Zhang, Z., Vuori, K., Wang, H.-G., Reed, J. C., & Ruoslahti, E. (1996) · Cell · doi:10.1016/s0092-8674(00)81082-x · Cited by 409
Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases
Feig, L. A. (1999) · Nature Cell Biology · doi:10.1038/10018 · Cited by 394
Self-citationEhrlich, J. S., Hansen, M. D. H., & Nelson, W. J. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00216-2 · Cited by 358
RAS and RHO GTPases in G1-phase cell-cycle regulation
Coleman, M. L., Marshall, C. J., & Olson, M. F. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1365 · Cited by 355
Ras-Independent Growth Factor Signaling by Transcription Factor Tyrosine Phosphorylation
Silvennoinen, O., Schindler, C., Schlessinger, J., & Levy, D. E. (1993) · Science · doi:10.1126/science.8378775 · Cited by 338
Interaction of the Nuclear GTP-Binding Protein Ran with Its Regulatory Proteins RCC1 and RanGAP1
Klebe, C., Bischoff, F. R., Ponstingl, H., & Wittinghofer, A. (1995) · Biochemistry · doi:10.1021/bi00002a031 · Cited by 324
THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS
Gibbs, J. B., & Oliff, A. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.143 · Cited by 324
Self-citationMoon, S., Cha, B., & Kim, C. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.10435 · Cited by 295
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
(2002) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(02)71047-7 · Cited by 280
John, J., Rensland, H., Schlichting, I., Vetter, I., Borasio, G. D., Goody, R. S., & Wittinghofer, A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54022-9 · Cited by 266
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Cox, A. D., & Der, C. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00011-5 · Cited by 266
The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation
Clark, G. J., Kinch, M. S., Rogers-Graham, K., Sebti, S. M., Hamilton, A. D., & Der, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10608 · Cited by 177
Babbey, C. M., Ahktar, N., Wang, E., Chen, C. C.-H., Grant, B. D., & Dunn, K. W. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-08-0799 · Cited by 164
Ehrhardt, G. R. A., Leslie, K. B., Lee, F., Wieler, J. S., & Schrader, J. W. (1999) · Blood · doi:10.1182/blood.v94.7.2433.419k31_2433_2444 · Cited by 54
Metadata
- Authors
- Stacey, D. W., Feig, L. A., & Gibbs, J. B.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1991-08
- Volume
- 11
- Issue
- 8
- Pages
- 4053-4064
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2176636090
- Cited by
- 163
- References
- 1
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.